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About 20% of breast cancer tumors over-express the HER2 receptor. Trastuzumab, an approved drug 
to treat this type of breast cancer, is a monoclonal antibody directly binding at the HER2 receptor and 
ultimately inhibiting cancer cell growth. The goal of our study was to understand the early impact of 
trastuzumab on HER2 internalization and recycling in the HER2-overexpressing breast cancer cell line 
SKBR3. To this end, fluorescence microscopy, monitoring the amount of HER2 expression in the plasma 
membrane, was combined with mathematical modeling to derive the flux of HER2 receptors from and 
to the membrane. We constructed a dynamic multi-compartment model based on ordinary differential 
equations. To account for cancer cell heterogeneity, a first, dynamic model was expanded to a second 
model including two distinct cell phenotypes, with implications for different conformational states 
of HER2, i.e. monomeric or homodimeric. Our mathematical model shows that the hypothesis of fast 
constitutive HER2 recycling back to the plasma membrane does not match the experimental data. 
It conclusively describes the experimental observation that trastuzumab induces sustained receptor 
internalization in cells with membrane ruffles. It is also concluded that for rare, non-ruffled (flat) cells, 
HER2 internalization occurs three orders of magnitude slower than for the bulk, ruffled cell population.
Many cancer types, including head and neck, stomach, colorectal, pancreatic, glioblastoma, lung, and breast car-
cinomas, are associated with the mutation or over-expression of the members of the human epidermal growth 
factor receptor family (HER1-4)1. Especially the HER2 over-expressed form of breast cancer, affecting 20% of the 
patients, has substantially attracted interest in clinical oncology and in the research community. This relates prob-
ably to the fact that it was one of the first malignant diseases for which a targeted therapy, namely the humanized, 
monoclonal anti-HER2 antibody trastuzumab, became available 20 years ago2. Compared to standard anti-cancer 
drug treatments, i.e. cytotoxic drugs without cancer specific molecular targets, trastuzumab combines impressive 
clinical efficacy with minimized side effects, similar to most other antibody-based targeted drugs3. However, the 
challenging issue of primary and acquired drug-resistance limits the benefits of trastuzumab, and of other bio-
logics4. Trastuzumab has several modes of action, including immune mechanisms, such as induction of antibody 
dependent cellular cytotoxicity (ADCC), and inhibition of HER2 mediated mitogenic signaling5. How the drug 
achieves the latter effect still remains controversial. Proposed are mainly the inhibition of receptor dimerization, 
and HER2 down-regulation by accelerated endocytosis and degradation6. To overcome trastuzumab resistance, 
more knowledge is needed about its mechanism of action, which, even after 20 years of prescription, is still too 
fragmentary. In this context it is also desired to take into account the role of cancer cell heterogeneity, which is 
considered as one of the hallmarks of cancer7. By combining single-cell data obtained with an improved HER2 
labeling, using a small binding probe, i.e. an anti-HER2 Affibody, and a fluorescent, non-quenchable quantum 
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dot label, and a description by mathematical modeling, we here set out to gain new insights. We focus on the 
very first effects trastuzumab exerts on HER2 overexpressing breast cancer cells, while accounting for inter- and 
intra-cellular heterogeneities.
Results
Fluorescence microscopy of trastuzumab-induced HER2 uptake. HER2 is abundant in the plasma 
membrane of SKBR3 cells, which is a well-established HER2 over-expressing breast cancer cell line and used in 
numerous in vitro studies8. To visualize membrane-bound HER2, we applied our previously established two-
step HER2 labeling protocol9,10. Live SKBR3 cells were first incubated for 10 min with a biotinylated anti-HER2 
Affibody. Affibodies are genetically engineered, small bacterial proteins, designed to bind with high affinity to 
a specific target protein. Functionally they imitate monoclonal antibodies, but they are 10 to 20-times smaller 
than antibodies. After a subsequent drug incubation, which was omitted for control cells, the cells were fixed 
and incubated with streptavidin quantum dots (QDs). The protocol ensures a 1:1 labeling stoichiometry between 
HER2 and QD. The fixation step was necessary to exclude artificial clustering and endocytosis of HER2, induc-
ible by multivalent QD labels11. Figure 1A shows the typical QD-fluorescence signature of SKBR3 cells. HER2 is 
distributed over the plasma membrane, whereby it locally accumulates in membrane ruffles and at the cell edges, 
consistent with previous studies9,12,13. Membrane ruffles are highly motile plasma membrane protrusions at the 
cell surface. From a top-view on SKBR3 cells, they usually appear elongated, almost worm-like, with a lateral 
thickness of ~0.5 μm in their short dimension and up to several microns in their long dimension. They are mainly 
localized towards the periphery of adherently grown cells. In addition, smaller, finger-like protrusions at the cell 
edges, or a cell surface speckled with dynamic “pimpled” structures, can be observed. Membrane ruffles contain 
densely polymerized actin filaments, as well as a multitude of actin-binding and -organizing proteins, which are 
often connected with transducing membrane receptor molecules such as the members of the HER family14,15. It 
should be noted that QDs do not penetrate through the plasma membrane, even after chemical fixation of the 
cells, the fluorescence signal is thus a measure of the HER2 expression at the plasma membrane only.
To determine drug-induced membrane clearance of HER2, the cells were exposed to trastuzumab at a con-
centration of 10 μg/mL. This dose had been shown to exhibit the maximal antiproliferative activity in SKBR3 
cells16,17, and was also used in other studies of trastuzumab induced HER2 internalization13,18 (see Fig. S1). In 
a first set of experiments, the cells were exposed to trastuzumab for different periods of time, ranging from 2 
to 60 min, followed by immediate fixation (e.g., Fig. 2). To examine a possible recycling route of uptaken HER2 
back to the membrane, we applied a two-phase technique, called a pulse-chase experiment (Table 1). During the 
pulse phase of the experiment, the cells were exposed to trastuzumab for different time periods. In the subse-
quent chase phase, the cells were incubated in drug-free cell culture medium until fixation. Thereafter, single-cell 
measurements of the mean QD fluorescence intensity allowed the quantification of the remaining plasma 
membrane-bound HER2. The Affibody was attached to HER2 prior to drug incubation in most experiments. The 
binding of the Affibody does not hamper the binding of trastuzumab19. To make sure that our Affibody incubation 
did not influence the examined drug-induced internalization process of HER2, we chose a high Affibody concen-
tration, resulting in an Affibody:HER2 ratio of ~50:1, supposed to saturate all HER2 binding sites. Furthermore, 
Figure 1. Analysis of membrane-bound HER2 level on SKBR3 cells. (A) Membrane-bound HER2 on SKBR3 
cells were labeled with an Affibody-quantum dot (QD) to visualize the locations of HER2. Light microscopic 
image from the QD fluorescence channel acquired for a control group of SKBR3 cells without drug incubation. 
The typical HER2 distribution, as found in the bulk cancer cells, is characterized by higher HER2 densities 
(appearing in orange and yellow) on membrane ruffles and at the cell periphery than in flat regions. Three rare 
flat/resting cells lacking membrane ruffles are marked with asterisks. The QD fluorescence signal is shown 
in false color (red hot LUT) to better discern the HER2 distribution patterns. (B) Overlay of the original red 
fluorescence channel image, with the corresponding direct interference contrast (DIC) channel image, yielding 
additional information of the membrane topography. These overlay images were used to manually mark all 
individual cells, except incompletely imaged cells at the image borders and small spherical cells. The marking 
resulted in distinctly coloured regions of interest each defining the area used for the measurement of total 
membrane-bound HER2 per cell, as calculated from the intensity in the QD-channel image. Scale bars: 100 μm.
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Figure 2. Trastuzumab incubation reduces membrane-bound HER2 levels, and changes the cell membrane 
topography by abolishing membrane ruffles. Shown are images of the QD-fluorescence channel measuring 
membrane-bound HER2 represented in false color. (A) SKBR3 cells were first incubated for 10 min at 37 °C 
to label all membrane-bound HER2 with the Affibody, followed by 5 min of incubation with 10 μg/mL of 
trastuzumab at 37 °C, fixation, and QD labeling. Compared to control cells (see Fig. 1A), the 5 min drug 
incubation led to a loss of the typically higher HER2 densities on the cell peripheries and on membrane ruffles, 
as reflected by the absence of membrane areas with orange and yellow color. (B) Results of a pulse-chase 
experiment in which the Affibody-labeled cells were first incubated with trastuzumab as in A, but for 20 min, 
followed by wash steps and a 2 h chase period in medium at 37 °C, prior to fixation and QD labeling. Compared 
to A, the level of membrane-bound HER2 has reduced, membrane ruffles have completely disappeared, and a 
fraction of the cells have reacted by marked constriction. (C) Extension of the drug incubation to 1 h (without 
a subsequent chase time) leads to further reduction of membrane HER2 levels. (D) The depicted SKBR3 cells 
were first incubated for 60 min with trastuzumab, and then labeled with Affibody. This led to similar changes 
as shown in (C), thus, no reversal of the drug effect by reappearing/recycled HER2 was found. The images were 








control 0 — — 218
2 min 0 2 — 223
2 min chase 0 2 120 185
5 min 0 5 — 302
5 min chase 0 5 120 168
5 min chase aff bm 5 120 188
5 min chase5 0 5 300 218
5 min chase5 aff bm 5 300 189
20 min 0 20 — 209
20 min chase 0 20 2 202
60 min 0 60 — 198
60 min aff bm 60 — 176
Table 1. Conditions of the main dataset in which the cells are considered as one cell population. The 
conditions differ in the time point of Affibody treatment: either before the experiment (time = 0 min) or 
before measurement (bm), the drug treatment (none or 2–60 min) and an optional chase time. The number of 
measured cells per condition is given in the last column.
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we performed four different control experiments. First, the cells were incubated for 60 min just with the Affibody. 
After this time period, the measured amount of membrane-bound HER2 remained unchanged compared to a 
control group without any treatment (see Fig. S2). This confirmed that our Affibody incubation did not lead to 
uptake of HER2. In addition, three other control experiments were performed to test any Affibody influence on 
the drug effect. In these tests, the cells were first incubated with trastuzumab for different periods of time, and the 
Affibody incubation was done afterwards, directly before fixation. The results of these controls are represented 
by triangles in Fig. 3B, they indicate a similar reduction in the membrane-bound HER2 content, compared to the 
main experiments, in which the Affibody incubation was done before the drug incubation, shown by the round 
data points in Fig. 3B. Note, that in the main data sets, a slow dissociation of the Affibody from HER2 during 
the time period of drug incubation, resulted in lower values of membrane-bound HER2. We can thus conclude 
that under our experimental conditions, the Affibody did not alter the cellular reaction towards the drug. We did 
not examine the cells for altered gene expression or proliferation patterns, possibly caused by Affibody exposure, 
because these effects usually need longer time periods to develop than our experimental time frame. Also, possi-
ble effects of HER2 signaling changes were not considered, as these were not assumed to change HER2 internali-
zation or recycling behavior after drug exposure.
Cells were first incubated for 10 min with Affibody, then exposed to trastuzumab for 5 min (Fig. 2A), or for 
20 min followed by a 2 hour chase period (Fig. 2B), or for 60 min (Fig. 2C). Compared to untreated cells (see 
Fig. 1A), trastuzumab led to a significant decrease in membrane-bound HER2. To examine a possible recycling 
of endocytozed HER2, which would lead to a replenishing of HER2 in the plasma membrane, experiments were 
performed in which the Affibody incubation was done after the cells were incubated for 60 min with the drug 
(Fig. 2D). Thereby, all HER2 receptors in the plasma membrane would be labeled irrespective of their source: 
recycled or de-novo synthesized. As can be seen by comparing the HER2 signal intensities in (Fig. 2C,D), no dif-
ference was discernible (see also both green markers in Fig. 3B), thus excluding a significant recycling of internal-
ized HER2 back to the plasma membrane during the 60 min chase period. To examine the existence of a possibly 
slower recycling process, pulse chase experiments were performed in which the drug incubation was followed by 
a chase period of 2 or 5 hours, during which the cells were in growth medium without drug. Also in these exper-
iments, no indication for a recycling process was found (compare the positions of the corresponding round and 
triangle markers in Fig. 3B).
Figure 3. Testing of HER2 recycling model. (A) Schematic representation of the recycling model. The Affibody 
binding process is not shown. The processes represented in grey color were found negligible and removed for 
the final fitting results. (B) Experimental data points and trajectories of the final fit of the recycling model, 
normalized by dividing by the scaling constant sc. (C) Fluxes with relevant contributions in the final fit of the 
recycling model for the condition with 60 min trastuzumab treatment, normalized by sc. The sign of the flux was 
chosen such that the backward processes (disassociation and recycling) are negative while all other processes 
give positive fluxes.
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Analysis of trastuzumab-induced HER2 uptake. Fluorescence microscopy data was acquired from sev-
eral hundreds of cells for each experimental group. An overview of the experimental groups is shown in Table 1. 
The data was quantified by measuring the mean QD fluorescence signal intensity per cell as measure of the HER2 
membrane density. For this purpose, the outline of each cell was manually indicated in each image and the corre-
sponding mean fluorescence intensity for the QD fluorescence channel was determined using the software of the 
microscope manufacturer (Leica), see Fig. 1. After background correction, these values were used for calibration 
of a mathematical model as described below.
Difference between cell phenotypes. To examine the drug effect in more detail, we considered the pres-
ence of different cell phenotypes in the heterogeneous cancer cell population. The single-cell data were thus 
grouped into distinct phenotypic subpopulations. As was found in a previous study, trastuzumab-induced HER2 
uptake predominantly takes place in bulk/ruffled cancer cells, while flat/resting cells without membrane ruffles 
(examples are marked with an asterisks in Fig. 1A,B) do not exhibit significant uptake20. A set of experiments with 
different timings and controls was performed to determine the difference between flat- and ruffled membrane 
areas in the drug-induced HER2 clearance from the plasma membrane. In these experiments, the cells were 
inspected for their ruffling status using direct interference contrast (DIC) microscopy images combined with 
time lapse imaging, and subsequently grouped into two phenotype-specific groups. One group contained the flat/
resting cells, defined as having none or only a single ruffle. The other group included all bulk cells that had more 
than one ruffle (for details see20). The data from these experiments were then used to build a refined mathematical 
model that included two distinct cell populations with different trastuzumab-induced HER2 uptake rates (see 
below).
A mathematical model of receptor recycling. As first approach to evaluate the involved receptor pro-
cesses, a mathematical model was implemented describing the receptor trafficking processes following a simi-
lar approach as described in literature21. This model did not consider the cellular heterogeneity of SKBR3 cells, 
consequently only one population is assumed. A schematic representation of the model is shown in Fig. 3A. 
According to the model, receptors can either be located in the membrane, denoted as Nm, or inside the cell, 
denoted as Ni. There are four processes involved in receptor trafficking:
 1. Production of new receptors including their insertion into the plasma membrane with rate kprod.
 2. Internalization of receptors from the membrane into intracellular compartments with flux kint · Nm.
 3. Recycling of internalized receptors back to the membrane with flux krec · Ni.
 4. Degradation of internalized receptors with flux kdeg · Ni. (Note:The degradation rate refers to the removal of 
receptors from the pool of receptors that has the capability to recycle back to the membrane. The degrada-
tion process itself may take much longer and is not part of this model).
It was assumed that the system was in equilibrium before the Affibody label and drug were added. This allows 
one to express two rate constants as functions of other parameters: kdeg = kprod/Ni(t = 0) and kint = (kprod + krec · Ni(
t = 0))/Nm(t = 0), where Ni(t = 0) and Nm(t = 0) correspond to the initial value parameters of Ni and Nm. Once 
trastuzumab with amount T was added to the liquid surrounding of the cells, binding of trastuzumab to the recep-
tors took place at the extracellular side of the plasma membrane. Drug binding in turn activated a process that led 
to the internalization of HER2 receptors with bound trastuzumab20,22–27. The exact mechanism leading to the 
internalization upon drug binding is unknown but was assumed to occur via cross-linking of HER2 homodimers 
by the antibody20. In our model, the binding of trastuzumab to the receptor was included in an activation flux 
kact · Nm · T that describes the transition of Nm to the state Nm
T, which then transitions to the internalization process 
governed by the internalization rate kint.
Note that the actual binding rate of trastuzumab to the receptor was possibly higher than the activation rate. 
Note furthermore that the activation of the HER2 internalization process should not be confused with the activa-
tion of the receptor for signaling. The drug can also dissociate leading to the reverse reaction with flux ⋅k Nm
T
diss . 
The receptors with bound trastuzumab Nm
T  internalize with a different rate constant kint,T compared to the 
unbound receptors.
Moreover, the rate constants for recycling and degradation of the internalized receptors with bound trastu-
zumab Ni
T very likely differed from those of receptors without bound trastuzumab, and were therefore allowed to 
take different values krec,T and kdeg,T. Similar as in the plasma membrane, trastuzumab can dissociate from the 
internalized receptor Ni
T once inside the cell. Because data on the latter process are not available, we assumed that 
it returned to the state Ni with the same rate constant kdiss as when bound to HER2 in the plasma membrane. To 
describe the availability of trastuzumab during the time course of the experiment, the trastuzumab amount T was 
implemented as the product of the initial amount of trastuzumab NT and a switch son: T = NT · son with
=
.{s 0 no Tavailable1 T availableon
The switch son also allows to represent the washing off of trastuzumab in case of pulse-chase conditions. 
During drug treatment, the number of trastuzumab molecules exceeded the number of receptors by a factor of 
roughly 40, since about 2.5 · 104 L of 69 nM (1 · 1013) trastuzumab were added to a dish of about 1.4 · 105 cells with 
about 2 · 106 receptors per cell (~3 · 1011 receptors). The absolute number of HER2 present in the dish was calcu-
lated by counting the number of cells from the control group of a typical drug exposure experiment, in a repre-
sentative, 0.25 mm2 large area of a cell culture dish, multiplied by a factor of 1000, to account for the total area of 
2.5 cm2, and assuming an average number of HER2 per cell to be 2 · 106 (considering a reported range of 1.4 · 106 
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to 7.2 · 106 HER2/cell28,29). In the mathematical model, the ratio of initial amounts of trastuzumab and receptors 
was therefore fixed by NT(t = 0) = 2.5 · 104 · Nm(t = 0).
The Affibody state A was implemented similar to trastuzumab, as a product of a switch and the ini-
tal amount of Affibody A0 = A(t = 0). About 1.8 · 10−4 L of 0.2 μM Affibody were added, giving a ratio of 





 ⋅ = .
A
N t
0 no Affibody available
50 ( 0) Affibody availablem
0
It was assumed that the presence of the Affibody did not affect any of the other rate constants, i.e. of the HER2 
trafficking, activation of trastuzumab-induced HER2 internalization, etc. The original equations describing recep-
tor trafficking were duplicated for Affibody-bound receptors. Additional terms were included to reflect that the 
Affibody can bind to both receptor states in the membrane, Nm and Nm
T, with rate constant kon yielding Nm
A and 
Nm
T A,  but cannot bind to internalized receptors. Yet, HER2 with bound Affibody Nm
A and Nm
T A,  may internalize 
yielding Ni
A and Ni
T A, . The Affibody can dissociate with rate constant koff from both receptors in the membrane 
(Nm
A, Nm
T A, ) and internalized receptors (Ni
A, Ni
T A, ). It should be noted, that the amounts of receptors with bound 
Affibody or trastuzumab were set to zero such that only Nm and Ni were available at the beginning of the 
experiment.
The full set of ordinary differential equations (ODEs) is given in Table 2. The modeled states N{m,i} are linked 
to the measured mean fluorescence signal Nobs via the observation function,






since the mean fluorescence signal was proportional to the mean density of Affibody-QD labeled receptors in the 
membrane. Due to the structure of the differential equations and the observation function, it was possible to 
simultaneously change the scaling parameter sc and the initial value parameter Nm(t = 0) in a way that left the 
predicted fluorescence signal Nobs unchanged. We used this freedom of scale to fix Nm(t = 0) to one, meaning that 
all receptor numbers Nm(t), N t( )m
T , Ni(t), N t( )i
T , N t( )m
A , N t( )m
T A, , N t( )i
A  and N t( )i
T A,  were expressed as multiples of 
the initial number of receptor on the membrane Nm(t = 0).
The model parameters were estimated from the data summarized in Table 1 using the maximum likelihood 
method. Optimization of the log-likelihood function from different initial guesses for all parameters revealed the 
existence of several local optima that describe the data almost equally well in terms of their log-likelihood value. 
To diminish the number of different solutions describing the data, additional assumptions were introduced to 
reduce the model complexity.
As a first step, solutions giving a larger fraction than 5% of internalized receptors (Ni/Nm) initially were omit-
ted, since most receptors were assumed to reside in the plasma membrane after the initial serum starving applied 
prior to the experiment; values of about 2.5% internalized HER2 under control conditions have been reported in 
literature30. The model was further simplified by imposing a limit range on the Affibody binding parameter kon, 
which excluded several solutions. Boundaries for the Affibody binding rate were extracted from measurements of 
cellular uptake published elsewhere31, leading to the range  . ⋅k A0 5 4on 0  1/min. The dissociation rate koff 
was estimated consistently between the different solutions within a narrow range of 0.5 · 10−3 to 1 · 10−3 1/min. 
This value is consistent with the value of 5 · 10−3 1/min (half-life τ = .2 2 h1
2
) in the literature31. A common feature 
of the remaining solutions was that an upper bound for the receptor synthesis process kprod < 1.5 · 10−4 1/min was 
derivable. A half life of τ = .9 4 h1
2
 was reported for HER2 receptors on a non-starved HER2 positive N87 gastric 
cancer cell line32. Starvation is expected to reduce this value by about 50% (ref.33). Accordingly, the production 
rate in starved N87 cells would be kprod ~ 6 · 10−4 1/min, which is in a similar range as the upper bound we found. 
On the other hand, synthesis rates between N87 and SKBR3 cells do not necessarily have to coincide. For a pro-
duction rate kprod tending to zero, also the degradation process kdeg · Ni must decrease because, otherwise, the 
d
dt Nm = kprod − kact · Nm · T + kdiss · − kNm
T
int · Nm + krec · Ni − kon · A · Nm + koff · Nm
A
d
dt Ni = kdiss · Ni
T  + kint · Nm − krec · Ni − kdeg · Ni + koff · Ni A
d
dt Nm
T  = kact · Nm · T − kdiss · − kNm
T
int ,T · Nm
T  + krec,T · −kNi
T
on · A · Nm
T  + koff · NmT A,
d
dt Ni
T  = −kdiss · NiT  + kint,T · − kNm
T
rec,T · − kNi
T
deg,T · Ni
T  + koff · NiT A,
d
dt Nm
A = −kact · NmA · T + kdiss · − kNm
T A,
int · Nm
A + krec · Ni A + kon · A · Nm − koff · NmA
d
dt Nm
T A,  = kact · NmA · T − kdiss · − kNm
T A,
int ,T · Nm
T A,  + krec,T · NiT A,  + kon · A · − kNm
T














T A,  = −kdiss · NiT A,  + kint,T · − kNm
T A,
rec,T · − kNi
T A,
deg,T · − kNi
T A,
off  · Ni
T A,
d
dt T = −kact · Nm
A · T + kdiss · − kNm
T A,
act · Nm · T + kdiss · Nm
T
d
dt A = −kon · A · Nm + koff · −kNm
A
on · A · Nm
T  + koff · NmT A,
Table 2. List of differential equations for the recycling model. The HER2 receptor N is labeled with suffix m or i 
indicating its location either on the membrane or internal. Bound Trastuzumab T or Affibody A are indicated by 
the superscripts T and A.
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receptor distribution in equilibrium would change. Omitting both, production and degradation process from the 
model did not deteriorate the fit. Therefore, in favor of the smaller model, these two processes were neglected.
Finally, three solutions remained with different parameters but no significant difference in the goodness of fit, 
measured by a likelihood ratio test. The main difference between the solutions was whether or not recycling and 
internalization of receptors was needed in the absence of trastuzumab.
Again, in favor of the smaller model, both, recycling and internalization of receptors that had not bound tras-
tuzumab were removed from the model. The other solutions are discussed in the Supplementary Information. 
A schematic representation of the final model is shown in Fig. 3A, whereby all processes neglected in the final 
results are shaded gray.
The experimental data and the fitted trajectories of the final model are shown in Fig. 3B. The trajectories of 
the model are in close agreement with the datapoints. In particular, the observed two time-scales are also present 
in the model, a fast reduction of receptors in the membrane within the first five minutes followed by a slower 
reduction of receptors from about 5 to 60 minutes are reproduced. The parameter values and their 95% confi-
dence intervals as being computed by the profile likelihood method (shown in Supplementary Information) are 
reported in Table 3. The time-resolved flux contributions for all processes are shown in Fig. 3C. All parameters 
are identifiable apart from the drug-induced internalization and recycling rates, where only lower bounds were 
defined. It turns out that the strong fluxes are needed to describe the two time-scales for the reduction of receptors 
in the membrane. The values of the drug-induced internalization and recycling rates are extremely large, predict-
ing that on average, the whole receptor population recycles back and forth from the membrane five times per 
minute. This is a non-physiological fast rate. For example, the fastest known receptor recycling rates occur in cells 
in the so-called rapid recycling pathway in the endosomal sorting machinery34–37, and these are at least two orders 
of magnitude slower than the value fitted here. Since it is non-physiological that the whole receptor population is 
renewed several times per minute, we conclude that the model does not accurately describe the involved biolog-
ical mechanisms. It was therefore questioned, whether other processes should be implemented in the model to 
alternatively describe the two time-scales. A suggested model extension is presented in the next section.
Extended model with membrane ruffles. Because the first model resulted in a non-physiological high 
recycling rate of trastuzumab-bound HER2, we developed a second model, extended by consideration of two 
distinct cell phenotypes, reflecting observations that SKBR3 cells can be grouped into different subpopulations 
with respect to the phenotype of their membrane topography. For this purpose, the entire SKBR3 population 
was divided into a large fraction of bulk cells, having a highly dynamic, ruffling plasma membrane, and a small 
fraction (~6%) of resting, or flat cells, with no or at most one membrane ruffle. As we have shown that homodi-
meric HER2 is only found in the ruffled bulk cell subpopulation9 we concluded that a direct correlation links the 
existence of ruffles with homodimeric HER2 and the efficiency of the drug to induced HER2 down-regulation 
from the plasma membrane20. The main experimental dataset (Table 1) was re-evaluated discriminating between 
the flat and ruffled cell phenotypes for the first few time points up to 5 min. It was impossible to make this dis-
crimination for time points larger than 5 min because trastuzumab incubation led to a vanishing of the ruffles 
in bulk cells. To track the cells over a longer drug treatment period of 60 min, a new experimental series was 
Parameter Model A Model B Unit
kact · T0 0.39 ± 0.09 1/min
kact,R · T0 0.4 ± 0.1 1/min
kact,F · T0 0.41* 1/min




kon · A0 1.0 ± .0 7
20 1.0** 1/min
koff 6.4 ± .
.
4 1
5 3 6.8 ± 4.1 10−4/min
kint,T 12.8 ± .
∞
12 1 1/min
kint,RT 49 ± ∞47 1/min
kint,FT 0.0126 ± 0.0028 1/min
krec,T 20 ± ∞19 NA*** 1/min
kdeg,T 0.87 ± .
.
0 79
0 90 NA*** 10−2/min
sc 529 ± 26 535 ± 27
Nm(t = 0) 1****
NF(t = 0) 0.62 ± 0.065
NR(t = 0) 0.38****
Table 3. Parameter values obtained by the model fit for the first, basic model (Model A) and second, extended 
model (Model B). For the parameters related to the drug or Affibody binding, effective rates (kact · T0, kon · A0) 
with T0 = T(t = 0) and A0 = A(t = 0) are given. The uncertainties correspond to 95% confidence intervals 
obtained from the parameter profiles. No upper bounds were found for the kint,T, krec,T and kint,RT parameters, 
therefore ∞ is given for the upper uncertainty. *The difference between kact,R and kact,F was estimated to zero, 
therefore kact,R = kact,F. **In case of Model B, the kon parameter was non-identifiable and fixed to the value from 
Model A. ***The second, extended model B was fitted without recycling and degradation processes. ****The 
initial value for the number of receptors (Model A: Nm, Model B: NR + N F) on the membrane is fixed to one.
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performed in which the cell phenotype was determined before the drug was added (Table 4), and the individual 
cells were tracked through the course of the experiment. At the end of the experiment, membrane-bound HER2 
was QD-labeled and quantified.
Figure 4 shows the normalized QD fluorescence intensity indicating membrane-bound HER2 as obtained 
from the single-cell, background corrected, distribution histograms of the mean QD fluorescence intensities for 
both datasets. In the main dataset, already at the first examined time points of 2 and 5 min, the flat and the ruf-
fled cells show a different reponse to the drug. This effect is even more pronounced in the additional dataset (see 
Fig. 4) after the 60 min treatment duration, when the bulk cells have clearly decreased their membrane-bound 
HER2 levels. In the flat control cell population without drug incubation, a lower mean HER2 fluorescence inten-
sity is observed than for the ruffled control cells. At the early time points, only a slight decrease is observed for the 
flat cells, after 60 min of drug incubation no difference is found versus the control flat cells. These cells are thus 
resistant against drug-induced HER2 internalization.
Ruffled cells contain ruffled and flat membrane regions. As the receptors in the flat regions of bulk cells are 
expected to behave similar to receptors on entirely flat cells, the advanced model distinguishes between receptors 
from flat and ruffled regions rather than between flat and ruffled cells. The overall proportion of receptors from 
Condition Cell Type Drug [min] Nr of Cells
control flat flat — 38
control ruffled ruffled — 69
min flat flat 60 66
min ruffled ruffled 60 74
Table 4. Conditions of the additional dataset in which the cells were considered either as ruffled, in case more 
than one membrane ruffle was found, or as flat, in case no or at most one membrane ruffle was found. The cells 
were incubated with Affibody before the experiment, and then incubuated with drug for 60 min drug. A control 
experiment without drug was also performed. No chase period was applied. The number of measured cells per 
condition is listed in the last column.
Figure 4. Normalized HER2 bound QD fluorescence intensity distribution. Shown is the difference in 
trastuzumab induced HER2 removal from the membrane between bulk cells, characterized by more than one 
membrane ruffle per cell (upper graphs), and flat cells, with no or only one membrane ruffle per cell (lower 
graphs). The main data set (left side) depicts the early reactions after 2 min (orange), and 5 min (green) of drug 
incubation, compared to control cells without drug incubation (blue). The validation dataset (right), determined 
after 60 min of drug incubation, shows a marked shift of the median of the ruffled bulk cell population towards 
median values of the flat cell population, indicating a more than 50% reduction of membrane-bound HER2 
within the bulk subpopulation. The mean HER2 signal distribution of the control flat cells started at already 
lower mean intensity values, compared to the ruffled cells. At early time points these cells exhibited only small, 
negligible shifts towards lower intensity values, after 60 min this subpopulation completely failed to show a 
difference towards the untreated flat cell population.
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flat regions in the whole SKBR3 cell population is thus higher than the 6% share of flat cells. The exact value is 
estimated together with the other model parameters.
In the advanced model, HER2 receptors from the ruffled and the flat membrane regions are denoted as NR and 
NF, see Fig. 5A. The observed receptors on the membrane thereby consist of contributions of both populations: 







T A, , , this is the receptors with and without trastuzumab (T) in the ruffled 
regions (R) plus the receptors with and without trastuzumab in the flat regions (F). Receptors can only contribute 
to the observation if they have bound the Affibody (A). Same as for the first, basic model, the freedom of scale is 
used to fix NR(t = 0) + NF(t = 0) to one. This means that NF(0) and NR(0) already reflect proportions of the total 
receptor population.
The drug binding to the receptors in flat and ruffled regions is fitted independently, the disassociation however 
is assumed to be the same. The increase to four different receptor states on the membrane also leads to an increase 
of different internal states and their corresponding trafficking processes. Although different and independent 
recycling processes for the different receptor populations can not be excluded, a straightforward implementation 
of all possible reactions with independent rate parameters would lead to a heavy over-parameterization of the 
model. Therefore, the model reductions found for the first, basic modeling approach, i.e. omission of receptor 
production and degradation, were also adopted for the second, extended model. The second model reaches out 
to find an answer to the possibility of fast recycling of the internalized receptor. As a radical approach, the model 
was tested under the restriction that no recycling process is allowed. In this case, also the degradation process 
can be neglected from the model since no interactions are left for the internalized receptors that would influence 
the receptor population on the membrane. The model was thereby reduced to describe drug-induced receptor 
internalization on two time-scales.
A schematic representation of the extended model is provided in Fig. 5A. The Affibody binding rate kon was 
fixed to the value found for the previous fit, given in Table 3. The extended model was calibrated based on the 
main experimental data set and fits this data equally well as the model with fast recycling, indicated by the trajec-
tories in Fig. 5B.
According to the model fit, NF(0) = 62 ± 10% of all membrane-bound HER2 present in the whole SKBR3 cell 
population are attributed to the flat membrane regions. The estimated internalization rate for receptors in ruffles 
is about a factor 1000 faster than for those in flat membrane regions. In contrast, the association rates for recep-
tors in both regions are estimated to the same value and need no distinction. The model parameters of the final, 
reduced model are reported in Table 3.
Figure 5. Testing of extended model including SKBR3 cancer cell heterogeneity. (A) Schematic representation 
of the model with ruffled and flat receptor populations on the membrane. (B) Fitted model trajectories with 
data points. (C) Model trajectories separated for the contributions of ruffled and flat regions for the control and 
60 min trastuzumab treatment conditions.
1 0Scientific RepoRtS |         (2019) 9:12709  | https://doi.org/10.1038/s41598-019-49019-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
In earlier studies we found HER2 on flat membrane regions to exist in the monomeric state9, and resisting 
trastuzumab induced internalization20. Although two HER2 monomers can be forced into a dimer by a com-
monly bound, bivalent molecule of trastuzumab27, these dimers seem to be too small to effectively induce their 
endocytosis. In contrast, the 38% fraction of HER2, located in ruffled membrane regions, and consisting for a 
large part of HER2 homodimers, can be linked by trastuzumab into large, chain-like oligomers. Compared to the 
very low constitutive internalization rate of HER2 in control cells30,38, the supposed trastuzumab-linked chains 
of HER2 homodimers can quickly start endocytosis, with a 1000-fold increased internalization rate. It is known 
that cross-linking with antibodies redirects receptors from a recycling into a degradation pathway, a switch that 
depends on the size of the cross-linked oligomers39, with larger oligomers likely being too bulky to be included in 
the tubules of the endocyctic recycling compartment40. Our data of sustained HER2 clearance from ruffled cells, 
confirmed by the results from experiments with Affibody labeling after long-term drug incubation (see Fig. 5B), 
are in complete agreement with these findings. The combined effect of the two different internalization rates is 
divided in Fig. 5C where the model prediction is shown separately for the two receptor populations in case of the 
60 min trastuzumab treatment.
To test whether the data could be described even more accurately, we reintegrated trastuzumab-induced recy-
cling and degradation processes and estimated the parameters again. It turned out that the additional parame-
ters could not significantly improve the fit. The question if a fast HER2 recycling process would be necessary to 
explain the data was thereby answered negative. It can thus be concluded that after trastuzumab-induced HER2 
internalization, no fast recycling process is needed to explain the experimental results.
Judging from the size of the error bars in Fig. 5B, it is imaginable to find models that fit the data more accurate. 
However, it should be kept in mind that the data points do not all correspond to the same sample or batch of 
SKBR3 cells. The error bar reflects the standard error of the mean fluorescence of each sample but does not cover 
inter-sample variability. Cancer cells are continually evolving, a characteristic that is responsible for the typical 
tumor cell heterogeneity and also accounts for differences between cell batches derived from the same cell line or 
tumor, but at different passage numbers, respect. different times41,42.
The model, without recycling process, was validated based on the additional data set (Table 4) which was to 
this point not used for model calibration. The ratio of the number of membrane receptors after 60 min trastu-
zumab treatment and before has been quantified for both cell populations. The values with their 95% confidence 
interval are reported in Table 5.
The observed ratios indicate a strong internalization in ruffled cells whereas the number of membrane recep-
tors on flat cells does not significantly change. The observed ratios are compared to the model prediction for cells 
with 100% flat regions and cells with a mixture of 60% of HER2 in flat and 40% in ruffled regions, as found by 
parameter estimation in the main dataset. Although the model correctly predicts a stronger internalization in 
ruffled cells than in flat cells, the predicted ratios are significantly smaller than observed in the validation dataset. 
A possible cause could be the above mentioned variability between cancer cell populations of different batches 
of the cell line over time, affecting the phenotype of ruffling behavior or the usuage of the same activation flux 
for ruffled- and flat cells, although a different flux would possibly be needed but was not implemented to avoid 
over-paramerization.
Discussion
An important hypothesis about the mechanism of the HER2 targeting antibody-drug trastuzumab involves 
drug-induced HER2 down-regulation. Although the general mechanism of antibody-induced clustering and 
endocytosis of membrane receptors is known since the early 1980’s43, and has been shown to also apply for several 
HER2 antibodies44,45, accumulation of conflicting results hampered a clear consensus in the case of trastuzumab. 
Already the first effect of trastuzumab, after binding its target on the cell membrane, is still a vivid matter of 
debate. While a down-regulation of HER2 signaling as a consequence of trastuzumab binding is generally well 
accepted, it remains controversial how this effect is achieved. Several studies reported a lack of internalization 
of HER2 and/or a fast recycling of HER2 back to the membrane13,18,23,46–48. These studies are challenged by pub-
lications demonstrating convincing data of substantially and prolonged HER2 localization in intracellular ves-
icles after incubation with trastuzumab22,24–26,44,48–50. Our own data support the latter results20. The discrepancy 
between those groups of studies is possibly explained by methodological limitations.
The first issue concerns fluorophore self-quenching, an effect appearing when fluorophores come into close 
proximity51. In experiments using fluorophore-labeled antibodies, this effect has been shown to bias the quanti-
fication of internalized HER252. Our hypothesis is that trastuzumab rapdily cross-links HER2 homodimers into 
large oligomers at the extracellular side of the plasma membrane, that are subsequently up-taken via endocyto-
sis. HER2-bound fluorophores will thus be present in endosomes in which they will become highly condensed, 










 + [95% 
conf. int] model prediction
flat 0.94 [0.78, 1.13] 0.66
ruffled 0.44 [0.35, 0.54] 0.29
Table 5. Ratio of the number of membrane receptors after 60 min trastuzumab treatment and before for a sub-
population of flat cells and ruffled cells for the validation dataset and the model prediction calibrated on the 
main dataset.
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amplified in case antibodies are used containing a multiple of dye molecules per antibody53, and when polyclonal 
secondary antibodies are used.
The second technical pitfall relates to the cooling of live cells on ice, as is done in many studies, especially those 
using flow cytometry. Cooling mammalian cells to 4 °C can induce major changes in the cytoskeleton through 
loss or damage of actin54. Prolongued cold incubation of cells is known to be responsible for several unwanted 
effects, such as artifactual immobilization of membrane receptors, artifactual cross-linking, and non-specific 
binding of nanoparticle-antibody probes, applied as specific labels for membrane receptors55. A significantly 
changed binding behavior of Pertuzumab, another therapeutic, monoclonal anti-HER2 antibody, was observed 
on cooled cancer cells56. Also in case of the closely related HER1 (EGFR) receptor, cooling the cells on ice induced 
marked changes in its membrane distribution57. Results from our control experiments, examining the cooling of 
SKBR3 cells on ice for a 60-min period, followed by a rewarming period to 37 °C, during which trastuzumab was 
applied, revealed changes in the HER2 plasma membrane distribution after the cooling period and, more impor-
tantly, a marked attenuation of the drug effect, compared to cells continuously kept at 37 °C before and during 
drug incubation (see Fig. S3).
A third problematic bias can be introduced through the use of rather bulky antibodies as labels for HER2, 
because antibody labeling is prone to the risk of steric hindrance58,59. In the case of HER2, this can reduce HER2 
label density, and thus lead to different HER2 labeling efficiencies between membrane regions of dense HER2 
occurrence, such as ruffles and endosomes, compared to flat membrane regions. In addition, when cells are fixed 
with formaldehyde before fluorophore conjugated trastuzumab is applied to label HER253, the risk of measure-
ment bias is even higher, because trastuzumab’s binding kinetics dramatically deteriorate on chemically fixed 
HER260.
Our approach circumvented the above-mentioned experimental pitfalls. To alleviate any bias of the quantifi-
cation of HER2 fluorescence caused by intravesicular fluorophore self-quenching51, we measured the remaining 
amount of membrane-bound HER246. Moreover, we used adherent, sub-confluently grown, living cells, and a 
continuous experimental temperature of 37 °C, thereby preserving the local environment of the cells (e.g. cell 
density) and normal physiological properties of adherent cells. Secondly, the label consisted of an anti-HER2 
Affibody, which is 10 times smaller than an antibody and not hampering the binding of trastuzumab19. Only at 
the end of the experiment, thus after the drug incubation, and in some cases after an additional chase period, the 
cells were chemically fixed. Fixation was necessary to prevent artificial HER2 clustering, which can be induced 
on live cells by multivalent QDs. This two-step labeling of membrane-bound HER2 with QDs allows direct quan-
tification due to its one-to-one labeling ratio with HER29, and in addition, it minimizes the risk of fluorophore 
self quenching. Single-cell datasets, reflecting the actual membrane levels of HER2, were collected at different 
time points of drug treatment. To examine a possible recycling mechanism a set of experiments with the drug 
incubation and different chase periods performed prior to the Affibody labeling was performed (see triangle 
markers in the graph of Fig. 5B). Another set of experiments was performed to examine possible differences in the 
drug effect on monomeric or homodimeric HER2. To this aim, the SKBR3 cell population was divided into two 
subpopulations, depending on the presence of membrane ruffles, which are the only regions were HER2 exists as 
homodimer.
The descriptive power of mathematical models of biological processes with ordinary differential equations 
(ODEs) critically depends on the quality of the underlying biological data. While the model structure itself is 
generic and has been used in the past to study HER2 trafficking e.g. in epithelial cells21, the parameters can vary 
considerably between different cell types and different experimental conditions. Difficulties in comparing data 
and conclusions gained from different HER2 (over)expressing cell lines can result from large variations between 
the absolute HER2 expression levels and different ratios between HER2 and its possible heterodimerization part-
ners, mainly HER1 (EGFR) and HER361. According to our hypothesis, all conditions lowering the share of HER2 
homodimers in the plasma membrane will probably reduce trastuzumab induced HER2 internalization. Several 
groups, including us, have shown that HER2 receptors in over-expressing cells accumulate in ruffled membrane 
regions12,13,62,63. Remarkably, these highly dynamic structures are the exclusive regions where we found HER2 in 
a homodimeric conformation9, responding within a few minutes to trastuzumab by disappearance20. The degree 
of membrane ruffling in HER2 positive cells often correlates with the absolute level of HER2 over-expression12, 
but, there are also reports on breast cancer cell lines with similar HER2 levels, but different degrees of membrane 
ruffling64. Trastuzumab is able to bind to both, monomeric and homodimeric HER227, but the fate of the two 
types of HER2-trastuzumab complexes differ largely. It is highly probable, that in regions with a high density of 
HER2 homodimers, trastuzumab creates large, chain-like oligomers, consisting of alternating HER2 homodimers 
and trastuzumab molecules, which are able to initiate their uptake by endocytosis. Trastuzumab binding to HER2 
monomers or heterodimers can only lead to smaller multimeric complexes, lacking the ability of initiating the 
endocytosis mechanism40. The situation is even more complicated by the interplay between HER2 and HER1, 
which is demonstrated by EGF-induced enhancement of dynamic membrane behavior65, the absolute level of 
HER2 surface expression, and HER2 turn-over rate66. These effects depend on the concentration of EGF in the 
surrounding medium or buffer, as well as the actual cell density, providing EGF for paracrine and autocrine 
stimulation67. The gathering of quantitative results on drug induced HER2 uptake, even when performed with 
the same cell line, is thus highly sensitive to a multitude of experimental conditions. Earlier published models 
on trastuzumab-induced HER2 internalization53,61,68,69, fall short with respect to the above described technical 
pitfalls of fluorophore self-quenching, artifacts due to prior cell detachment, fixation preceding labeling, and 
low temperature effects. Not surprisingly, all these models implement substantial HER2 recycling rates, probably 
because they would not fit without this assumption.
Apart from these technical hurdles, a common weakness in the design of most studies examining the effect of 
trastuzumab on HER2 internalization is the neglect of cellular heterogeneity, nowadays considered as hallmark of 
cancer70. Heterogeneity within the overall cell population is reflected by the existence of for instance rare resting/
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dormant cancer cells71. In addition, heterogeneity can also be found at the sub-cellular level, for instance in the 
form of flat and ruffled membrane regions. Through individual single-cell sorting of SKBR3 cells into ruffled bulk 
cells, or flat cells, we were able to build a second, extended model that considered the different conformations 
of HER2 as homodimers and monomers. This model showed an improved descriptive quality compared to the 
first model, build without any differentiation of SKBR3 cells into subpopulations. We did not include HER2 
heterodimers with other members of the receptor family, because of the several-fold lower expression levels of 
these other HER family members in SKBR3 cells. The ratio of expressed HER2 versus expressed EGFR under our 
experimental conditions, including serum starvation, is around 2029, and the ratio of HER2:HER3 is even 40, 
HER4 expression is below the detection limit72. These proportions leave HER2 heterodimers a minor fraction 
compared to HER2 homodimers73.
Focusing exclusively on the quantities of membrane-bound HER2, our data showed a robust and sustained 
HER2 down-regulation after trastuzumab incubation. Any significant HER2 recycling process would have 
resulted in the attenuation or reversal of this down-regulation, or the recycling parameter would have to be set in 
a non-physiologically high range. By considering HER2 heterogeneity, our second, extended mathematical model 
allowed eliminating a recycling process without deterioration of the data description.
Conclusions
Our data show that trastuzumab induces a sustained down-regulation of membrane-bound HER2. The extent of 
this decrease depends on the exposure time, ranging from 30% average reduction after only 2 minutes to about 
60% after 60 minutes. Considering the individual cells, the degree of HER2 reduction strongly depends on the 
existence of HER2 homodimers in membrane ruffles. Furthermore, the data indicate a negligible restocking of 
HER2 on the membrane.
Our first, basic model is capable of explaining the observed behavior without consideration of cellular heter-
ogeneity. However, this model requires the implementation of extremely high internalization and recycling rates, 
two orders of magnitude higher than known rates for recycling. Because the fitted exceptionally high recycling 
rate appears to be non-physiological, we developed a second, extended model that considers the spatially segre-
gated presence of HER2 in different functional states, i.e. homodimeric and monomeric, preferentially located 
on ruffled, respectively flat membrane regions9. Due to their different susceptibility to chain-like cross-linking 
by trastuzumab, these two functional states of HER2 have highly different internalization rates. Based on the 
estimated parameters, the extended model explains the observed data for physiologically realistic process rates. It 
explains why binding of the same drug to HER2 in two distinct membrane regions20 can lead to two greatly differ-
ing consequences for HER2, namely (a) sustained internalization, or (b) unaffected residency in the membrane. 
The drug effect as seen on the level of the whole cell population reflects the overall degree of ruffling in the bulk 
cell population, including the percentage of flat, resting, or dormant cells without membrane ruffles. Intra- and 
inter-cellular heterogeneity is known to play a crucial role in cancer and its therapeutic combat. By increasing the 
precision of the underlying datasets, consideration of heterogeneity can thus substantially improve the interpre-
tation of observed drug effects in cancer cells through mathematical models.
Methods and Materials
Materials. SKBR3 cells were obtained from ATCC. Biotin and fluorescein conjugated Anti-HER2 Affibody 
Molecule (HER2-AFF-B, termed: (ZHER2:477)2) was purchased from Affibody AB, Bromma, Sweden. 
Dulbecco’s Phosphate Buffered Saline (DPBS), Dulbecco’s Modified Eagle’s Medium GlutaMAXTM with high 
glucose and pyruvate (DMEM), Fetal Bovine Serum, certified, heat inactivated (FBS), Minimum Essential 
Medium Non-Essential Amino Acids (NEAA) 100× solution, Phosphate Buffered Saline (PBS) 10× solution, 
CellStripper, Normal Goat Serum (GS), and Quantum Dot (QD) Qdot 655 Streptavidin Conjugate (Strep-QD) 
were from Fisher Scientific GmbH, Schwerte, Germany. D-Saccharose, Glycine, biotin free and molecular biology 
grade Albumin Fraktion V (BSA), and Sodium Cacodylate Trihydrate were from Carl Roth GmbH + Co. KG, 
Karlsruhe, Germany. Electron microscopy grade Formaldehyde (FA) 16% solution was from Science Services 
GmbH, Munich, Germany. HPLC grade deionized Water, 0.01% poly-L-lysine (PLL) solution (mol wt 70,000–
150,000), Sodium Tetraborate, Boric Acid, and Fibronectin-like Engineered Protein Polymer-plus (FLEP), were 
from Sigma-Aldrich Chemie Gmbh, Munich, Germany. 35 mm-cell culture dishes with uncoated glass bot-
tom were from Greiner bio-one, Frickenhausen, Germany (CELLviewTM four compartments), and from ibidi, 
Munich, Germany (μ-Dish, with imprinted 50 or 500 μm relocation grid).
35 mm-cell culture glass bottom dishes preparation for cell settlement. All glass bottom dishes 
were prepared for SKBR3 cell settlement by hydrophilization with Ar/O2 plasma for 5 min and subsequent incu-
bation with 0.01% PLL, 500 mL per compartment, in four compartment dish, 2 mL for grid imprinted dishes 
without compartments, for 5 min at room temperature (RT). Afterwards, the dishes were rinsed twice in HPLC 
grade water, incubated in FLEP (15 μg/mL in water, 3.7 μg/cm2) for 5 min, rinsed twice in PBS, and kept in FBS 
supplemented cell medium until the cell suspension was ready (within 10–15 min).
Cell culture and cell seeding on cell culture dishes. SKBR3 cells (human breast cancer cell line overex-
pressing HER2) were cultured in flasks (25 cm2) with cell media (DMEM, supplemented with 1% NEAA and 10% 
FBS), in a 5% CO2 atmosphere, at 37 °C. The cells were passaged twice a week at 60–80% confluency. Experiments 
were performed with cells between passages 6 to 22. The cells were harvested by rinsing in DPBS, dissociation 
with CellStripper (15–20 min, at 37 °C), and quenching with 4.5 mL of full cell media. 300–400 μL, respect. 1.0–
1.5 mL, of the SKBR3 cell suspension were added to each dish compartment, respect. to a grid imprinted dish, 
aiming to achieve 60–80% cell confluency on the next day. The next day, the cell media were exchanged to leave 
the cells under serum starvation overnight.
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Trastuzumab incubation and labeling of HER2. Cells grown to 70–90% confluency at day 2 after seed-
ing were subjected to drug exposure and HER2 labeling, performed as described earlier9. To examine the effect 
of 10 μg/ml trastuzumab (diluted in cell culture medium without serum) on the density of HER2 in the plasma 
membrane, the cells were exposed to trastuzumab for different periods of time, lasting between 3 min and 24 h, 
with or without subsequent chase periods in cell media without drug, lasting 2 or 5 h. All incubation and chase 
periods were performed at 37 °C in the CO2 incubator, and the live cells were never cooled to RT for more than 
a few minutes, and never cooled below RT. For investigating a possible recycling of internalized HER2 back to 
the plasma membrane, HER2 labeling with HER2-AFF-B was done before or after selected time periods of drug 
incubation, with or without subsequent chase periods. Before incubation with Strep-QD (5 nM in PBS including 
1% BSA (BSA-PBS)) the cells were fixed with 3% formaldehyde (FA) and processed with rinsing and quenching 
steps as described earlier9.
Direct interference contrast (DIC) and fluorescence microscopy. At the end of the drug exposure 
and HER2 labeling experiment, the cells were kept in BSA-PBS, and imaged in an inverted light microscope 
(DMI6000B, Leica, Germany) using two different channels, a DIC analyzer filter cube, to yield information about 
membrane borders and topography, such as membrane ruffles, and a filter cube with a 340–380 nm excitation and 
>420 nm emission window for QD emission. In most experiments a 20× objective was used, except for exper-
iments designed to examine the influence of membrane ruffles, where a 40× objective was used. The imaging 
settings within the experimental groups and between the experiments were kept identical.
Experiments to investigate the involvement of ruffles on the drug effect. After 2 days, includ-
ing overnight serum starvation, SKBR3 cells that were grown in glass bottom dishes with imprinted grids, were 
imaged in CO2 independent medium for at least 15 min, at 37 °C, with time lapse light microscopy using the DIC 
channel, recording tiled images from randomly chosen areas of areas of 1 μm2. The cells were then exposed for 
1 h to trastuzumab with subsequent HER2-labeling as described above, followed by recording a second DIC and 
a QD emission image of the same areas. Control cells were processed similar, except that the drug was lacking 
during the 1 h drug incubation step. For the characterization of cellular subpopulations into ruffled/bulk or flat/
resting cells, we determined the criterion for the later to be the complete absence or the presence of only a single 
ruffle per cell. All cells with more than one ruffle were sorted into the bulk cancer cell group. In addition, all cells 
sorted into the flat/resting cells group were checked in the time lapse data set to truly exhibit a resting behavior, 
i.e. lacking the appearance of more than 1 ruffle during the 15 min time window of time lapse imaging.
Quantification of membrane-bound HER2 in control and in drug exposed cells. The recorded 
images were analyzed using the Leica Application Suite X (LAS-X) software, including a first visual screening of 
the images to exclude cells, which did not comply with our general criteria for analysis, i.e. cells of spherical shape 
and of small size9, i.e. <600 μm2. In addition, cells that were only partially captured within the image frame were 
also excluded from further analysis. In general, all other cells were analyzed, except in experiments designed to 
examine the effect of membrane ruffles, where, due to the high number of imaged cells, the analyzed bulk cells 
were randomly determined until a similar number of cells was reached, comparable to the cell numbers in the 
other experiments. All cells cleared for further analysis were manually marked around their cell border, whereby 
the enclosed area represented the cell adherence area to the supporting glass. In this defined region of interest 
(ROI) the signals deriving from all QD-labeled HER2 on the respective cell were determined. The following 
values from the LAS-X analysis were used from the analyzed cell ROIs: (a) mean signal intensity per pixel, in the 
following referred to as luminosity, and (b) total HER2 signal intensity of the cell, i.e. the sum of all fluorescence 
pixel values within the ROI, as determined from the QD fluorescence channel and given as ‘grey values’. In addi-
tion, also the cell adherence area size was measured. To correct these values for unspecific background signal, 
created by the reflections of QD emitted light in the dishes, 3 to 4 regions of interest without cells were marked 
in every image. The average value of the mean signal intensity per pixel of these background ROIs was calculated 
for every image, and subsequently subtracted from the values of the cell ROIs in that image. In later experiments 
the individual background level was measured close to every single analyzed cell ROI and subtracted from the 
respective cell ROI values.
Data preprocessing. The main dataset contained measurements for twelve conditions, differing in the 
length of treatment with trastuzumab and the time-point of labeling the receptors with the Affibody (before or 
after the drug treatment). About 200 cells were marked per condition providing information on their size (area) 
and luminosity. For each condition several pictures were acquired from different areas in the cell culture dish. All 
completely captured cells in the images were analyzed. Due to luminosity variations between the images also 
background areas were marked and measured for each image. Aim of the data pre-processing was to extract one 
comparable signal value, corrected for the background, for each condition. A detailed description of the signal 
pre-processing is given in the Supplementary Information. In summary, the signal per condition sc was deter-
mined by a least squares estimation based on = +s s bc p
obs
c p,  where the mean luminosity per cell was used as input 
for the observed signal sc p
obs
,  and the mean background luminosity per picture bp corresponding to the observed 
background per picture =b bp
obs
p was added.
Mathematical Modeling. The receptor dynamics model was described by a set of reactions that were math-
ematically formulated as ordinary differential equations (ODEs), following mass-action kinetics. A model pre-
diction was generated by solving the ODEs numerically for a given set of parameters, which consisted of initial 
amounts of the receptor states and the rate constants associated with the reactions. In general, the system was 
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assumed to be in equilibrium at t = 0. This steady-state assumption induced relations between the rate constants 
and initial amounts that allowed to reduce the number of free parameters. The treatment of the cells with the 
Affibody or trastuzumab was implemented by switches that regulated the availability of these compounds. When 
available, the compounds could bind to the receptors leading to observability in case of the Affibody or altered 
reaction rates in case of trastuzumab.
The measured signal was proportional to the sum of Affibody bound receptors on the membrane. The pro-
portionality factor was included in an observation function in order to allow the comparison of the simulated 
receptor time-courses with the measured time-resolved signal. For the optimization process, the model predic-
tion xc was scaled to match the observed signal sc, sc = ks · xc + ε, where the scaling factor ks was determined along 
with the other parameters of the model. In addition, we assumed that the measurement noise ε was normally 
distributed. For the presentation of the results, the data and model prediction were scaled inversely such that the 
predicted control condition corresponded to one at time point zero.
The free parameters were determined from the experimental data by the maximum-likelihood approach. The 




















where y(tc, θ) is the predicted observation at time point tc for condition c given the parameters θ. The symbol yc
D 
denotes the data point for condition c at time point tc and σc its uncertainty. Parameter estimates were obtained by 
minimizing eqn. (1) with respect to θ. The profile-likelihood method74 was applied to compute confidence inter-
vals of the parameters and to test whether all parameters were identifiable given the experimental data, The model 
was reduced until all parameters are identifiable, following methods described elsewhere75.
All model analyses, parameter estimation and identifiable analysis were carried out using the dMod76 
package for R. The package is available on the Comprehensive R Archive Network (CRAN). The structural 
non-identifiability of parameters due to scaling- and translation-symmetries was tested by a Lie-group approach77.
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